11 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Aug 2038. from the record
Of the 19 now held by other companies, 18 name Lonza Sales AG as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2038
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Sep 2029 · High confidence
The most cited patent in this portfolio, cited by 50 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2029.
now held by Lonza Sales AG
Also notable
Ends Aug 2038 · High confidence
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2038.
now held by Lonza Sales AG
Also notable
Ends Aug 2038 · High confidence
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
now held by Lonza Sales AG
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 4 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Process for Preparing Extracellular Vesicles | 2 in force | to May 2041 |
| Extracellular Vesicles for Vaccine Delivery | 2 in force | to Mar 2040 |
| Methods of Producing Extracellular Vesicles | 1 in force | to Oct 2043 |
| Sting Agonist Comprising Exosomes for Treating Neuroimmunological Disorders | 1 in force | to Apr 2043 |
| Treatment of Cancer Metastasis by Targeting Exosome Proteins | 1 in force | to Feb 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,257,313 | Preparation of Therapeutic Exosomes Using Membrane Proteins held by Lonza Sales AG In force · Low confidence | In force | Low confidence | |
| US 12,331,100 | Exosomes for Immuno-Oncology and Anti-Inflammatory Therapy held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,357,571 | Loading of Extracellular Vesicles Through Imparting of Mechanical Shear held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,570,978 | Methods and Compositions for Macrophage Polarization held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 11,992,527 | Extracellular Vesicles for Vaccine Delivery held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,502,427 | Extracellular Vesicles for Vaccine Delivery held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,465,875 | Process for Preparing Extracellular Vesicles held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,233,356 | Process for Preparing Extracellular Vesicles held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,545,728 | Treatment of Cancer Metastasis by Targeting Exosome Proteins held by Lonza Sales AG In force · High confidence | In force | High confidence | |
| US 12,616,712 | Sting Agonist Comprising Exosomes for Treating Neuroimmunological Disorders held by Lonza Sales AG In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 19 patents in force now held by others · 42 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.